DSIP (Delta Sleep-Inducing Peptide)
100 mcg · Nightly
Evidence
- Human Studies
- 5
- Animal Studies
- 15
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Unknown — old, small studies with inconsistent results and essentially no modern controlled human trials
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
DSIP was originally isolated from rabbit brain in the 1970s and named for association with delta-wave (deep) sleep in early animal studies, though subsequent human research has produced inconsistent results and its mechanism is not well characterized. It is sold as a research chemical with limited modern clinical validation.
Common Protocols
- 100 mcg subcutaneous, taken shortly before bed, per informal research-community protocols — no established clinical dosing guideline exists
Side Effects
- Limited systematic data; anecdotal reports of vivid dreams
- Injection site irritation
Interactions
- No formal interaction data exists; caution combining with other sedating compounds
Practical Details
- Cost
- $
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution
Research Links
Sleep-promoting peptide; name is somewhat misleading, mechanism not fully understood